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Nevirapine resistance mutation at codon 181 of the HIV-1
reverse transcriptase confers stavudine resistance by increasing
nucleotide substrate discrimination and phosphorolytic activity
Abstract
Recombinant HIV-1 reverse transcriptase (RT) carrying non-nucleoside inhibitors (NNRTIs) resistance
mutation at codon 181 showed reduced incorporation and high efficiency of phosphorolytic removal of
stavudine, a nucleoside RT inhibitor. These results reveal a new mechanism for cross-resistance
between different classes of HIV-1 RT inhibitors.
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Recombinant HIV-1 reverse transcriptase (RT) carry-
ing non-nucleoside inhibitors (NNRTIs) resistance mu-
tation at codon 181 showed reduced incorporation and
high efficiency of phosphorolytic removal of stavudine,
a nucleoside RT inhibitor. These results reveal a new
mechanism for cross-resistance between different
classes of HIV-1 RT inhibitors.
Anti-human immunodeficiency virus type 1 (HIV-1)1 highly
active therapy, based on the combined use of nucleoside (NR-
TIs) and non-nucleoside (NNRTIs) reverse transcriptase (RT)
inhibitors, often select for multidrug resistance (1–3). To date,
three molecular mechanisms are known for NRTIs resistance:
(i) selective alterations in inhibitor binding and/or incorpora-
tion (discrimination), (ii) template/primer repositioning, which
influences NRTIs incorporation, and (iii) phosphorolytic re-
moval of an incorporated chain-terminating NRTI from the
3-end of the nascent DNA strand (4). In particular, the mech-
anisms of resistance to the NRTI stavudine (d4T) are still
elusive. High levels of d4T resistance appear concomitantly
with resistance to zacitalbine (ddC) and zidovudine (AZT) and
seem to correlate with the acquisition of complex patterns of
mutations, suggesting that it would be difficult for a single
mutation in the HIV-1 RT gene to decrease the incorporation
efficiency for d4T (5–10). In the present study we show, for the
first time, that a NNRTI resistance mutation at codon 181
selected by nevirapine (NVP) or other NNRTIs can contribute
to a decreased sensitivity to d4T inhibition, by two indepedent
resistance mechanisms: increased nucleotide selectivity and
specific phosphorolytic removal.
MATERIALS AND METHODS
Chemicals—NVP and d4T were purchased from Roche Molecular
Biochemicals and Bristol-Myers Squibb, respectively. [3H]dTTP (40 Ci/
mmol), [-32P]ATP (3000 Ci/mmol), and AZT triphosphate were from
Amersham Biosciencies. Poly(rA), oligo(dT), the 66- and 24-mer oligode-
oxynucleotides and unlabeled dNTPs were from Roche Molecular Bio-
chemicals. GF/C filters were supplied by Whatman. d4T triphosphate
was synthesized in the laboratory of the authors as reported previously
(11). All other reagents were of analytical grade and purchased from
Merck or Fluka.
Expression and Purification of Recombinant Wild Type and Mu-
tated (Y181I, Y188L, and K103N) HIV-1 RT Enzymes—The coexpres-
sion vectors pUC12N/p66(His)/p51 with the wild type or the mutant
(Y181I, Y188L, and K103N) forms of HIV-1 RT p66 were kindly
provided by Dr. S. H. Hughes (NCI-Frederick Cancer Research and
Development Center) and purified as follows (2). The Escherichia coli
strain JM109(DE3) harboring the corresponding expression plasmids
was grown at 37 °C in 1 liter Luria Broth to an A600 of 0.6. Isopropyl-
thiogalactoside was added to a final concentration of 1 mM, and
growth was continued for 4 h. Cells were harvested by centrifugation,
resuspended in 10 ml of buffer A (40 mM Tris (pH 8.0), 0.5 M NaCl, 1
mM PMSF), and subjected to a French press. The mixture was cleared
by centrifugation at 30,000  g for 30 min. The supernatant was
loaded on a 1-ml HiTrap Chelating column (Amersham Biosciences)
complexed with Co2 ions and equilibrated in buffer A. The enzyme
was eluted from the column with a 0–0.5 M imidazole HCl gradient
in buffer A. Pooled fractions were dialyzed against buffer B (50 mM
Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM 2-mercaptoethanol, 0.4 mM
PMSF, 10% (v/v) glycerol) and loaded onto a Mono S column (Amer-
sham Biosciences) equilibrated in buffer B. The HIV-1 RT proteins
were eluted from the column with a 50–500 mM NaCl gradient in
buffer B. Pooled fractions were dialyzed against 50 mM Tris-HCl (pH
7.5), 20% (v/v) glycerol, 1 mM EDTA, 1 mM dithiothreitol, 0.4 mM
PMSF. All enzymes were purified to 95% purity and had a specific
activity on poly(rA)/oligo(dT) of: HIV-1 p66(His)/p51, 75,670 units/
mg; p66(K103N)/p51, 96,415 units/mg; p66(Y181I)/p51, 65,770 units/
mg; p66(Y188L)/p51, 79,050 units/mg. 1 unit of DNA polymerase
activity corresponds to the incorporation of 1 nmol of dNMP into
acid-precipitable material in 60 min at 37 °C. All enzymes were
purified to 95% purity, as judged by silver-stained SDS-polyacryl-
amide gels.
Evaluation of HIV-1 RT DNA Polymerase Activity—RNA- and DNA-
dependent DNA polymerase activities were assayed as described in
the presence of 0.5 g of poly(rA)/oligo(dT)10:1 (0.3 M 3-OH ends), 10
M [3H]dTTP, and 2–4 nM RT. When the 5-32P-labeled d24:d66-mer
template was used, a volume of 10 l contained 0.05 M (3-OH ends)
of the DNA template and nucleotides as indicated in the figure
legends. After incubation at 37 °C, the products of the reaction were
separated on a 7 M urea/20% polyacrylamide sequencing gel. Quan-
tification of the products was performed by scanning the gel with a
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Amersham Biosciences PhosphorImager and integrating with the
program ImageQuant.
Steady-state Kinetic Measurements—Time-dependent incorporation
of radioactive nucleotides into the different template-primers at differ-
ent nucleotide substrate concentrations was monitored by removing
25-l aliquots at 2-min time intervals. Initial velocities of the reaction
were then plotted against the corresponding substrate concentrations.
When the 5-32P-labeled d24:d66-mer template was used, initial veloc-
ities after 10 min of incubation at 37 °C in the presence of different
substrate concentrations were calculated from the integrated gel band
intensities (see also below). For determination of the Km and kcat values,
an interval of substrate concentrations from 0.2 Km to 10 Km was used.
For Ki determination, an interval of inhibitor concentrations between
0.2 Ki and 5 Ki was used in the inhibition assays.
Kinetic Parameters Calculation—All values were calculated by non-
linear least squares computer fitting of the experimental data to the
appropriate rate equations. Km, Vmax, and kcat values were determined
according to the Michaelis-Menten equation. Ki values were calculated
according to the equation for competitive inhibition. The values of
integrated gel band intensities in dependence of the nucleotide sub-
strate concentrations were fitted to the equation: I*
T
/IT1  Vmax-
[dNTP]/(Km  [dNTP]), where T  target site, the template position of
interest and I*T  the sum of the integrated intensities at positions T,
T1 . . . Tn.
RESULTS AND DISCUSSION
Recombinant HIV-1 RT Carrying Mutated Codon 181 Shows
Reduced Sensitivity to d4TTP—The sensitivity of recombinant
HIV-1 RTs carrying NNRTIs resistance-associated mutations
to the inhibition by the dideoxynucleoside triphosphate analogs
ddTTP, ddCTP (the active form of zalcitabine), AZTTP (the
active form of zidovudine), and d4TTP (the active form of stavu-
dine) was tested in comparison with the wild type enzyme. As
can be seen from the results summarized in Table I, only the
mutation at codon 181 significantly reduced the affinity of the
enzyme for the dTTP substrate, with an increase of2.5-fold in
the measured Km values with respect to wild type RT. The
same mutation was also associated with an increase in the Ki
FIG. 1. HIV-1 RT with mutation at
codon 181 is less susceptible to d4T.
A, sequencing gel analysis shows a re-
duced accumulation of the products at po-
sition 2 (arrow) of the standard sub-
strate (d24:d66-mer, see “Materials and
Methods”), due to d4TTP incorporation,
for the mutant Y181I (lanes 2–7) in com-
parison with the wild type enzyme (lanes
8–13). B, quantification of the data from
the experiment in A shows a reduced af-
finity for d4TTP for the mutant (squares)
compared with wild type enzyme (circles).
C, effects of increasing concentrations of
ATP on the inhibition potency (Ki) values
for d4TTP for wild type (squares) or Y181I
HIV-1 RT (circles) on the RNA-dependent
DNA synthesis activity (see “Material and
Methods”). The ATP-dependent increase
of the Ki values was plotted against the
ATP concentrations. From the curves
shown, a maximum decrease in inhibition
potency (indicated by the increase of the
Ki values) of 11 ( 1)-fold and 2 (0.5)-
fold was calculated for Y181I and wild
type HIV-1 RT, respectively. D, sequenc-
ing gel analysis shows a more efficient
ATP-dependent phosphorolytic removal
of the incorporated d4TMP, reflected by
the disappearance of the products at po-
sition 2 (arrow) of the d24:d66-mer tem-
plate-primer by HIV-1 RT Y181I (lanes
7–12) with respect to the wild type en-
zyme (lanes 1–6).
TABLE I
Inhibition by nucleoside analogs of RNA-dependent DNA synthesis catalysed by HIV-1 RT wt and mutants
RT dTTP (Km)
Ki
ddTTP ddCTP AZTTP d4TTP
M M M M M
wt 4.2 (0.5)a 0.02 (0.001) 0.2 (0.03) 0.007 (0.001) 0.02 (0.005)
K103N 2 (0.2) 0.015 (0.001) NDb 0.006 (0.001) 0.03 (0.004)
Y181I 11 (0.5) 0.07 (0.01) 0.4 (0.05) 0.01 (0.002) 0.09 (0.005)
Y188L 3.5 (0.5) 0.02 (0.001) ND 0.002 (0.0005) 0.04 (0.005)
a Errors  S.D. calculated as described under “Materials and Methods.” Each value is the mean of three independent experiments. Significance
of the differences among the mean values obtained for wild type and mutated RT was p  0.05 according to a Student’s t test under the null
hypothesis that the mean values were equal.
b Not done.
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values for ddCTP, ddTTP, and d4TTP, with respect to wild type
RT. In contrast, no significant differences were found for
AZTTP inhibition.
Mutation at Codon 181 Specifically Reduces the Incorpora-
tion Efficiency of Deoxy- and Dideoxynucleoside Triphosphate
Analogs by HIV-1 RT—Recombinant wild type and mutant RTs
were analyzed for their ability to incorporate dTTP, dCTP,
ddCTP, AZTTP, and d4TTP on a heteropolymeric DNA sub-
strate, corresponding to nucleotides 1006–1071 (codons 169–
190 of the RT coding sequence) of the HIV-1 pol gene (HXB2
isolate). Fig. 1A shows the incorporation of d4TTP by HIV-1
wild type RT and for the 181 mutant. Quantification of the gel
bands intensities clearly showed a reduced efficiency of the 181
mutant RT in utilizing d4TTP as the substrate with respect to
wild type RT (Fig. 1B). As summarized in Table II, mutations
at codons 103 and 188 did not alter the incorporation efficien-
cies (kcat/Km values) for AZTTP, d4TTP, and dTTP with respect
to wild type RT. In contrast, the mutation at codon 181 de-
creased the incorporation efficiency for dTTP by 3-fold and for
d4TTP by about 15-fold. On the other hand, the 181-mutated
RT was able to incorporate AZTTP with efficiency similar to
wild type RT.
Mutation at Codon 181 Increases the Ability of RT to Dis-
criminate between dTTP and d4TTP—As summarized in Ta-
ble III, comparison of the incorporation efficiencies kcat/Km
for the natural substrates dTTP or dCTP and the cognate
dideoxy analogs AZTTP, d4TTP, or ddCTP indicated that the
dideoxy analogs were preferred as substrates to the corre-
sponding deoxynucleotides. However, compared with wild
type enzyme, discrimination between d4TTP and dTTP and
between ddCTP and dCTP was 5-fold and 2-fold, respectively,
more efficient with the 181-mutated RT. None of the other
NNRTIs-associated mutations significantly affected the spec-
ificity of the RT for the nucleotide analogs studied, with the
exception of the 188 mutation, which induced a 2.5-fold
higher preference for d4TTP incorporation over dTTP than
the wild type enzyme.
The 181 Mutant RT Is More Efficient in Removing d4TMP-
terminated Residues than the Wild Type Enzyme—One impor-
tant mechanism of NRTIs resistance by HIV-1 RT resides in its
ability to unblock a dideoxy-terminated primer by removing the
last incorporated nucleotide through a PPi- or ATP-dependent
phosphorolytic reaction. In a first series of experiments, the
ability of ATP or PPi to reduce the inhibition of either wild type
RT or 181-mutated RT by AZTTP and d4TTP was evaluated.
The reduction observed with AZTTP and d4TTP was compara-
ble for both enzymes in the case of the PPi-dependent pathway
(data not shown). On the other hand, in the ATP-dependent
pathway, the inhibition by d4TTP of the 181-mutated RT was
reduced more than 10-fold than in the case of wild type enzyme
(Fig. 1C). In a second series of experiments, phosphorolytic
removal by RT in the presence of ATP of the last incorporated
nucleotide from primers terminated by either d4TMP or
AZTMP (resulting in a shorter product) was directly visualized
by a polyacrylamide gel. As shown in Fig. 1D, the rate of
unblocking was higher for the 181-mutated RT (0.15 (0.01)
s1) than for the wild type enzyme (0.025 (0.01) s1) for
d4TMP. No significant differences were found for AZTMP (data
not shown).
The mutations Y181I/C are involved in high level NNRTIs
resistance, especially to nevirapine and delavirdine (1, 2).
The results presented in this study show, for the first time, a
role of a NNRTIs resistance mutation in contributing to d4T
resistance by two different mechanisms: increased nucleotide
selection and phosphorolytic removal (Table III and Fig. 1).
In addition, we recently showed that d4T could inhibit the
replication of a recombinant HIV-1 strain carrying the Y181C
TABLE II
Kinetic parameters of deoxy- and dideoxynucleoside triphosphate analogs incorporation catalyzed by wild type and mutated HIV-1 RT
Substrate
RT
Wild type K103N Y181I Y188L
dTTP
Km (M) 0.4 (0.05) 0.2 (0.02) 0.7 (0.05) 0.3 (0.05)
kcat (s
1) 0.05 (0.005) 0.03 (0.005) 0.03 (0.005) 0.03 (0.005)
kcat/Km (M
1 s1) 0.125 (0.005) 0.15 (0.05) 0.042 (0.005) 0.1 (0.02)
dCTP
Km (M) 9.5 (0.05) ND
a 13 (0.5) ND
kcat (s
1) 0.05 (0.005) ND 0.03 (0.005) ND
kcat/Km (M
1 s1) 0.0053 (0.0001) ND 0.0023 (0.0002) ND
ddCTP
Km (M) 0.2 (0.05) ND 0.4 (0.05) ND
kcat (s
1) 0.05 (0.001) ND 0.02 (0.005) ND
kcat/Km (M
1 s1) 0.25 (0.02) ND 0.05 (0.01) ND
AZTTP
Km (M) 0.015 (0.001) 0.014 (0.002) 0.022 (0.002) 0.01 (0.002)
kcat (s
1) 0.03 (0.005) 0.025 (0.001) 0.02 (0.005) 0.015 (0.005)
kcat/Km (M
1 s1) 2 (0.2) 1.8 (0.2) 0.9 (0.05) 1.5 (0.05)
d4TTP
Km (M) 0.02 (0.005) 0.03 (0.01) 0.09 (0.01) 0.01 (0.002)
kcat (s
1) 0.03 (0.005) 0.03 (0.001) 0.01 (0.002) 0.03 (0.002)
kcat/Km (M
1 s1) 1.5 (0.05) 1 (0.1) 0.1 (0.02) 3 (0.2)
a Not done. Errors  S.D. were calculated as described under “Materials and Methods.” Each value is the mean of three independent
experiments. Significance of the differences among the mean values obtained for wild type and mutated RT was p  0.05 according to a Student’s
t test under the null hypothesis that the mean values were equal.
TABLE III
Relative incorporation efficiencies of dideoxynucleoside triphosphates




wt 16 (0.5) 12 (0.5) 47 (2)
K103N 12 (0.3) 6.7 (0.2) NDb
Y181I 21 (1) 2.5 (0.2) 21 (2)
Y188L 15 (1) 30 (2) ND
a The relative efficiency is calculated as the ratio between the kcat/Km
values reported in Table II for the specified deoxynucleotides. Errors 
S.D. were calculated as described under “Materials and Methods.” Each
value is the mean of three independent experiments. Significance of the
differences among the mean values obtained for wild type and mutated
RT was p  0.05 according to a Student’s t test under the null hypoth-
esis that the mean values were equal.
b Not done.
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substitution, 5–10-fold less efficiently with respect to wt and
K103N mutant recombinant HIV-1 strains, thus confirming
the impact of mutations at codon 181 on d4T resistance.2
These effects are specific for d4T (since AZT sensitivity was
not significantly affected) and for the 181 mutation (since
other common NNRTIs resistance mutations such as K103N
or Y188L did not show any effect). The specificity observed
for the Y181I mutation can be related to the fact that the
changed amino acid is adiacent to the conserved catalytic
residues Asp185 and Asp186. It is reasonable to hypothesize
that this substitution alters the geometry of the active site of
HIV-1 RT, resulting in a less favorable interaction with the
nucleotide substrate. The fact that only d4T, but not AZT,
was affected might be related to the differences in the struc-
tures of these two thymidine analogs. In particular, the azido
group at the 3-position of the sugar ring of AZT is known to
stabilize binding of the drug to the enzyme. A major differ-
ence between AZT and d4T is that the latter drug bears a
carbocyclic pentose ring, lacking any substituent at both the
2- and 3-positions, thus d4T might be in principle more
sensitive to alterations in the nucleotide binding pocket.
These findings can have immediate clinical implications; cau-
tion should be applied when considering d4T for rescue treat-
ments following NNRTI-containing regimen failure, even in
patients not previously exposed to the drug.
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